Annual Congress Amsterdam 2011

Saturday, 24.09.2011
Sunday, 25.09.2011
Monday, 26.09.2011
Tuesday, 27.09.2011
Wednesday, 28.09.2011

Citations should be made in the following way: Authors. Title. Eur Respir J 2011; 38: Suppl. 55, abstract number.

Material from 2011

4205 Abstracts
632 Slide presentations
250 Webcasts
66 Handouts
1703 e-posters
250 Multimedia files

Material from 2011 Show

Bronchodilators in asthma and COPD

Thematic Poster Session
Chairs: M. Cazzola (Rome, Italy), R. Dahl (Aarhus, Denmark), C. Page (London, United Kingdom), R. Polosa (Catania, Italy)

Download all media

Efficacy of indacaterol is maintained in patients with moderate or less and severe or worse COPD S. Korn, O. Kornmann, L. Dunn, D. Lawrence, C. Lassen, B. Kramer (Mainz, Frankfurt, Germany; Clearwater, Hanover, United States Of America; Horsham, United Kingdom)
Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) use R. Dahl, C. Fogarty, D. Lawrence, C. Lassen, B. Kramer (Aarhus, Denmark; Spartanburg, Hanover, United States Of America; Horsham, United Kingdom)
The efficacy of the assistant use of short-acting β₂ stimulant procaterol on the daily activity in COPD patients. Niigata multicenter study K. Sakai, H. Nakayama, S. Hokari, R. Suzuki, A. Takiguchi, T. Takada, E. Suzuki, I. Narita (Niigata, Japan)
Onset of action and effect of withdrawal of roflumilast in COPD K. Rabe, T. Similowski, D. Bredenbröker, P. Teichmann, G. Böszörményi-Nagy (Grosshansdorf, Konstanz, Germany; Paris, France; Budapest, Hungary)
Doxofylline: Efficacy and safety in complex treatment of COPD T. Pertseva, K. Gashynova, N. Klimenko (Dnipropetrovsk, Ukraine)
Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD D. Singh, B. Leaker, A. Tutuncu (Manchester, London, United Kingdom; San Diego, United States Of America)
NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trial A. D‘Urzo, G. Ferguson, M. Kato, S. Atis, C. Martin, V. K. T. Alagappan, D. Banerji, Y. Lu, T. Overend (ON, Canada; Livonia, East Hanover, United States Of America; Osaka, Japan; Icel, Turkey; Horsham, United Kingdom)
NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial J. A. van Noord, K. Hirata, A. D‘Urzo, C. Martin, R. Horton, Y. Lu, T. Overend (Heerlen, Netherlands; Abeno-ku, Japan; ON, Canada; Horsham, United Kingdom; East Hanover, United States Of America)
Efficacy and safety of AZD3199, an inhaled ultra long-acting β₂-agonist, in patients with COPD P. Kuna, Y. Ivanov, V. Trofimov, O. Beckman, T. Bengtsson, C. Jorup, F. Maltais (Lodz, Poland; Pleven, Bulgaria; St. Petersburg, Russian Federation; Lund, Sweden; Quebec, Canada)
Clinical efficacy and patients‘ satisfaction for 100 consequent COPD patients using tiotropium respimat M. Kato, T. Teranishi, T. Kobayashi, Y. Izuhara, Y. Higami, Y. Koshimo, S. Marumo, K. Miura, M. Kawashima (Kishiwada, Japan)
Influence of tiotropium bromid on airway inflammation and symptom in COPD patients D. Ozol, H. Karaman, R. Akgedik, S. Uysal, R. Yigitoglu, Z. Yildirim (Ankara, Turkey)
The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD P. Short, D. Elder, P. Williamson, S. Lipworth, S. Schembri, B. Lipworth (Dundee, St. Andrews, Perth, United Kingdom)
Assessments of protective effects of tiotropium bromide against methacholine- and neurokinin A-induced bronchoconstriction in patients with asthma E. Derom, Y. Van Durme, B. Salhi, C. Vander Stichele, F. Bauters, J. Sele, R. Louis, G. Joos (Ghent, Liège, Belgium)
ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide E. Kerwin, S. Rennard, A. Gelb, L. Rekeda, E. Garcia Gil, C. Caracta (Medford, Omaha, Lakewood, Jersey City, United States Of America; Barcelona, Spain)
Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN A. Agusti, P. W. Jones, E. Bateman, D. Singh, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Barcelona, Spain; London, Manchester, United Kingdom; Cape Town, South Africa; , United States Of America)
The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) D. Singh, E. D. Bateman, P. W. Jones, A. Agusti, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Manchester, London, United Kingdom; Cape Town, South Africa; Barcelona, Spain; , United States Of America)
ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients A. Gelb, J. Donohue, A. D‘Urzo, L. Rekeda, E. Garcia Gil, J. Lateiner (Lakewood, Chapel Hill, Jersey City, United States Of America; Toronto, Canada; Barcelona, Spain)
Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN P. W. Jones, A. Agusti, E. D. Bateman, D. Singh, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (London, Manchester, United Kingdom; Barcelona, Spain; Cape Town, South Africa; , United States Of America)
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD M. Decramer, F. Maltais, G. Feldman, J. Brooks, L. Willits, S. Harris, G. Crater (Leuven, Belgium; Laval, Canada; Spartanburg, Rearch Triangle Park, United States Of America; Uxbridge, United Kingdom)
Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD C. Reisner, E. St. Rose, S. Strom, T. Fischer, M. Golden, M. Thomas, C. Orevillo (Morristown, Raleigh, United States Of America; Toowong, Australia)